Loading
Vanda Pharmaceuticals Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Polymeropoulos Mihael Hristos, was filed 08 Aug 2025.
Vanda Pharmaceuticals Inc.: what insiders have been doing
Vanda Pharmaceuticals Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 22 October 2026, brought 15 filings signed by 9 insiders.
Only sales appear on the open market, 6 sales in all totalling €2.4M, filed by 6 insiders. The largest single trade was a sale of €1.1M by Polymeropoulos Mihael Hristos, published on 4 March 2026.
Compared with its exchange (3,171 companies, median 24 filings), a count of 15 filings is below the norm. Our records for Vanda Pharmaceuticals Inc. go back to 2016, with 15 purchases and 160 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 216.1 m USD and net income of -220.5 m USD.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
350
Thresholds
n/a
Buy Volume
€476,243
15 ops. · all time
Sell Volume
€52M
160 ops. · all time
Who traded when
BuySaleMihael Hristos Polymeropoulos14 buys1 sale
Kevin Patrick Moran1 buy1 sale
Stephen Ray Mitchell2 sales
Gunther Birznieks1 sale
Joakim Wijkstrom1 sale
Tage Honore1 sale
+1 other insider
Since the insiders bought
- +19.8%Entry US$4.19 · Close at T+365 US$5.02
- +85.7%Entry US$4.46 · Close at T+365 US$8.28
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Vanda Pharmaceuticals Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$11.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,235 of 26,246 companies
26.8
score / 100
Value3
Quality50
FCF yld-45%
Earn yld-89%
EV/EBITDA·
ROE-78%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.09
Analyst consensus
5 analystsStrong buy
US$5.75Target US$11.75(+188%)US$20.00
Income statement
RevenueUS$216.1M
Gross profitUS$203.1M94% margin
EBITDA-US$139.3M-64% margin
Net income-US$220.5M-127.4% margin
Valuation
P/Book1.1x
Beta0.69
Balance sheet & cash
Market capUS$247M
Total debtUS$12.6M
Free Cash Flow-US$110.4M
Debt / Equity10%
Profitability & ownership
ROE-77.8%
ROA-22.4%
% insiders6.8%
% institutions87.5%
Last declaration on 8 June 2026
Declarations350 total
41,600 shares0Common StockSEC:0001193125-26-261811:0
41,600 shares0Common StockSEC:0001193125-26-261800:0
41,600 shares0Common StockSEC:0001193125-26-261806:0
57,101 shares0Common StockSEC:0002130896-26-000008:0
42,431 shares@ US$8.265958.5% of flowCommon StockSEC:0001702031-26-000002:0
156,235 shares@ US$8.173440.4% of flowCommon StockSEC:0001355537-26-000002:0
42,442 shares@ US$8.265943.3% of flowCommon StockSEC:0001806596-26-000002:0
30,800 shares@ US$8.265946.2% of flowCommon StockSEC:0001785888-26-000002:0
42,434 shares@ US$8.265940.6% of flowCommon StockSEC:0001748392-26-000002:0
30,000 shares@ US$8.03100.0% of flowCommon StockSEC:0001193125-26-067185:0
125,000 shares0Common StockSEC:0001193125-26-059784:0
125,000 shares0Common StockSEC:0001193125-26-059781:0
125,000 shares0Common StockSEC:0001193125-26-059778:0
125,000 shares0Common StockSEC:0001193125-26-059792:0
525,000 shares0Common StockSEC:0001193125-26-059770:0
10,000 shares@ US$4.151.3% of flowCommon StockSEC:0000950170-25-105819:0
Canonical exit: 5 Nov 2025 (T+90)
7,000 shares@ US$4.5913.8% of flowCommon StockSEC:0000950170-25-087025:0
59,225 shares0Common StockSEC:0000950170-25-083890:0
59,225 shares0Common StockSEC:0000950170-25-083889:0
59,225 shares0Common StockSEC:0000950170-25-083888:0
59,225 shares0Common StockSEC:0000950170-25-083885:0
59,225 shares0Common StockSEC:0000950170-25-083884:0
481 shares@ US$4.390.0% of flowCommon StockSEC:0000950170-25-076012:1
Canonical exit: 19 Aug 2025 (T+90)
9,519 shares@ US$4.401.4% of flowCommon StockSEC:0000950170-25-076012:0
Canonical exit: 19 Aug 2025 (T+90)
20,000 shares@ US$4.22362.8% of flowCommon StockSEC:0000950170-25-074565:0
Canonical exit: 14 Aug 2025 (T+90)
25 of 350 declarations
About Vanda Pharmaceuticals Inc.
From a competitive standpoint, Vanda operates in highly contested specialty markets where differentiation depends on clinical efficacy, safety profile, intellectual property protection, and commercial execution. The company focuses on niche therapeutic areas rather than mass markets, which can support attractive margins if launches succeed, but also increases binary risk tied to FDA decisions and clinical trial outcomes. Recent 2026 public updates highlighted regulatory progress around imsidolimab and the commercial launch of NEREUS in the United States, while also indicating that certain HETLIOZ-related regulatory requests faced unfavorable outcomes. For investors, Vanda therefore looks like a healthcare name with a high risk/reward profile, highly sensitive to FDA catalysts, Fanapt sales momentum, and the company’s ability to translate its pipeline into recurring revenue.
